Seer, Inc. (SEER)
NasdaqGS · USD · Healthcare · Biotechnology
$1.93 (-2.03%) as of
Key statistics
- Market cap
- 106.87M
- Forward P/E
- -1.83
- EPS (TTM)
- -1.2200
- Dividend yield
- 0.00%
- 52-week range
- 1.5500 – 2.3900
- Beta
- 1.47
- Revenue (TTM)
- 14.22M
- Profit margin
- 0.00%
- Analyst target
- $4.00
- Volume
- 59.31k
About Seer, Inc.
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Redwood City, CA, United States
- Employees
- 124
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.